Mitoquinone/Mitoquinol Mesylate as Prophylaxis for Severe Viral Illness

Phase 2, open-label trial of mitoquinone in respiratory viral infection and coronavirus disease 2019 (COVID-19) (2 arms), sponsored by University of California, Los Angeles. Primary endpoints: Number of Participants With Viral Illness at 14 days and Severity Score of Symptoms of Viral Illness at 14 days. Started Apr 2022; status: completed.